{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=88",
    "query": {
      "intervention": "cohort 2",
      "page": 88
    },
    "page_size": 10
  },
  "pagination": {
    "page": 88,
    "page_size": 10,
    "total_count": 7396,
    "total_pages": 740,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=89&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=87&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T22:38:43.082Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00790010",
      "title": "Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab Plus Ipilimumab Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab Plus Ipilimumab Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab Plus Ipilimumab Cohort 3",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab Plus Ipilimumab Cohort 4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2009-02-26",
      "completion_date": "2018-06-22",
      "has_results": false,
      "last_update_posted_date": "2023-05-11",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00790010"
    },
    {
      "nct_id": "NCT02265510",
      "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors",
        "Advanced Malignancies",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "INCB052793",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "azacitidine",
          "type": "DRUG"
        },
        {
          "name": "pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "INCB050465",
          "type": "DRUG"
        },
        {
          "name": "INCB039110",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2014-09-10",
      "completion_date": "2019-02-27",
      "has_results": true,
      "last_update_posted_date": "2020-04-17",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02265510"
    },
    {
      "nct_id": "NCT06150924",
      "title": "Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mineralys Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-12-14",
      "completion_date": "2025-04-23",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 44,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06150924"
    },
    {
      "nct_id": "NCT00696124",
      "title": "Safety Study of Gene Therapy in Treating Critical Leg Ischemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "VM202 2 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VM202 4 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VM202 8 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VM202 16 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Helixmith Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "20 Years to 90 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-04-03",
      "completion_date": "2023-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-10-06",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00696124"
    },
    {
      "nct_id": "NCT05216835",
      "title": "Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Classical Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Sabestomig (AZD7789)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "101 Years",
        "sex": "ALL",
        "summary": "16 Years to 101 Years"
      },
      "enrollment_count": 45,
      "start_date": "2022-03-18",
      "completion_date": "2025-09-04",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05216835"
    },
    {
      "nct_id": "NCT00066625",
      "title": "Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2003-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-01",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066625"
    },
    {
      "nct_id": "NCT05313191",
      "title": "Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "CNS Cancer",
        "Head and Neck Cancer",
        "GI Cancer",
        "Gynecologic Cancer",
        "Prostate Cancer",
        "Thoracic Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pencil Beam Scanning Proton Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "The New York Proton Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1800,
      "start_date": "2022-01-24",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05313191"
    },
    {
      "nct_id": "NCT02262910",
      "title": "Study of ES414 in Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ES414",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aptevo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 35,
      "start_date": "2015-01",
      "completion_date": "2019-02-18",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Buffalo, New York • Temple, Texas + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Temple",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02262910"
    },
    {
      "nct_id": "NCT03573310",
      "title": "A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Solid Tumor, Adult",
        "Non-Hodgkin Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "JNJ-64619178",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2018-07-13",
      "completion_date": "2025-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 4,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03573310"
    },
    {
      "nct_id": "NCT03867682",
      "title": "Venetoclax and Lintuzumab-Ac225 in AML Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Relapsed Adult AML"
      ],
      "interventions": [
        {
          "name": "Lintuzumab-Ac225",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Actinium Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2020-01-15",
      "completion_date": "2024-06",
      "has_results": false,
      "last_update_posted_date": "2023-08-04",
      "last_synced_at": "2026-11-20T22:38:43.082Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Louisville, Kentucky • New Orleans, Louisiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867682"
    }
  ]
}